Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cerenis Therapeutics (Cerenis), a biopharmaceutical company developing new lipoprotein (HDL) therapies to treat cardiovascular and other metabolic diseases, and Groupe Novasep (Novasep), a supplier of manufacturing solutions to the life sciences industries, have received French Government funding through OSEO to finance the development of CER-001, a Cerenis HDL mimetic.
Subscribe to our email newsletter
Cerenis and Novasep claimed that CER-001 represents a new approach in the fight against atherosclerotic cardiovascular disease and has shown preclinical efficacy in promoting reverse lipid transport. The program is currently in Phase 1 clinical development for the treatment of post-acute coronary syndrome patients.
The funding from OSEO is expected to allow the further progression of Cerenis’ new HDL therapy for orphan disease applications, which represent the unmet need and the potential for an accelerated development pathway.
Cerenis and Novasep have collaborated on the process development for CER-001 since 2007, focusing on downstream processing of the recombinant protein component. Under this funding and an expanded agreement, Novasep is expected to be responsible for the manufacturing of clinical and initial commercial supplies for the orphan drug development program.
Jean-Louis Dasseux, president and CEO of Cerenis, said: “This is an exciting step toward the development of better treatments for cardiovascular disease. We look forward to expanding our relationship.”
Antoine Baule, president of novasep process, the bioprocess division of Novasep, said: “We are delighted to be working with Cerenis to further optimise the manufacturing process.”